CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS
A replay of the call will be available for one year and can be accessed via NASHVILLE, Tenn., July 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its second quarter 2024 financial results and provide a company update after the market closes on Tuesday, Aug. 6, 2024.
2024年7月30日田纳西州纳什维尔——专业药品公司坎伯兰药业（纳斯达克股票代码：CPIX）今天宣布，将于2024年8月6日星期二收盘后发布2024年第二季度财报并提供公司更新。
A conference call will be held on Aug. 6 at 4:30 p.m. Eastern Time to discuss the results. To participate in the call, please register at
将于美国东部时间8月6日下午4:30举行电话会议，讨论财报结果。请在以下网址注册参加电话会议：
Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them. Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.
注册后，与会者可以通过拨打支持的电话号码并输入个人识别码号码接入会议。或者，他们可以选择“呼叫我”选项，在会议开始时自动由系统呼叫他们。
A replay of the call will be available for one year and can be accessed via Cumberland's website or by visiting .
电话会议录音将保留一年，并可通过坎伯兰药业的网站或访问链接进行获取。
Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments.
坎伯兰药业是一家专注于提供改善患者护理的独特产品的专业药品公司。公司开发、收购和销售医院急性护理、胃肠病和肿瘤市场领域的产品。
The company's portfolio of FDA-approved brands includes:
公司的FDA批准品牌包括：
- Acetadote (acetylcysteine) injection, for the treatment of acetaminophen poisoning;
- Caldolor (ibuprofen) injection, for the treatment of pain and fever;
- Kristalose (lactulose) for oral solution, a prescription laxative, for the treatment of constipation;
- Omeclamox-Pak, (omeprazole, clarithromycin, amoxicillin) for the treatment of Helicobacter pylori (H. pylori) infection and related duodenal ulcer disease;
- Sancuso (granisetron) transdermal system, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment;
- Vaprisol (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; and
- Vibativ (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.
- 乙酰半胱氨酸针剂（Acetadote），用于治疗对乙酰氨基酚中毒；
- 注射用布洛芬(Caldolor)，用于治疗疼痛和发烧；
- 口服轻泻剂卢通露司（Kristalose），用于治疗便秘；
- 奥美拉唑，克拉霉素，阿莫西林套装（Omeclamox-Pak），用于治疗幽门螺杆菌感染和相关的十二指肠溃疡病；
- 格拉司琼（Sancuso），透皮给药系统，用于预防接受某些化疗治疗的患者的恶心和呕吐；
- 康维普坦（Vaprisol）针剂，用于提高住院患者中的保健和高容量低钠血症的血清钠水平；
- 特拉凡芳（Vibativ）针剂，用于治疗包括医院获得性和呼吸机相关性细菌性肺炎以及复杂的皮肤和皮肤结构感染在内的某些严重细菌感染。
The company also has a series of Phase II clinical programs underway evaluating its ifetroban product candidate in patients with cardiomyopathy associated with Duchenne Muscular Dystrophy and Systemic Sclerosis. Additionally, Cumberland recently received FDA clearance to proceed directly to a Phase II study for patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease.
该公司还展开了一系列第二期临床项目，评估其伊莎替罗班产品候选人在肌萎缩性侯谢氏肌肉萎缩症和全身性硬皮病患者中的心肌病的治疗。此外，坎伯兰最近获得FDA的审批，直接进行了关于原发性肺纤维化患者的第二期研究，这是逐渐进展的间质性肺病最常见的形式。
For more information on Cumberland's approved products, including full prescribing information, please visit links to the individual product websites, which can be found on the company's website at .
有关坎伯兰已批准的产品的更多信息（包括完整的处方信息），请访问公司网站上链接到各个产品网站的链接： .
SOURCE Cumberland Pharmaceuticals
参考来源：坎伯兰药业
